摘要
目的探究信迪利单抗联合奥沙利铂及卡培他滨在晚期食管癌患者治疗中的临床效果。方法选择2018年5月至2021年5月在南阳医学高等专科学校第二附属医院就诊的98例晚期食管癌患者作为研究对象,并根据治疗方案分为A组(38例)和B组(60例)。A组使用紫杉醇及顺铂联合治疗,B组使用信迪利单抗、奥沙利铂及卡培他滨联合治疗。比较2组近、远期疗效及治疗前后血清免疫功能指标水平。结果B组完全缓解率、客观有效率、疾病控制率均高于A组(χ^(2)=4.540,P=0.033;χ^(2)=8.425,P=0.004;χ^(2)=4.952,P=0.026)。A组患者的中位疾病无进展生存期为4.9个月,中位总生存期为5.0个月,B组分别为8.0、11.5个月。截至随访终点,B组患者的中位疾病无进展生存期和中位总生存期均高于A组(P=0.008、0.017)。A组、B组患者治疗后血清IgA、IgG、IgM水平较治疗前升高(A组:t=0.332,P=0.741;t=0.141,P=0.888;t=0.557,P=0.579;B组:t=4.307,P<0.001;t=9.751,P<0.001;t=3.983,P<0.001);治疗后,B组血清IgA、IgG、IgM水平高于A组(t=2.642,P=0.010;t=7.855,P<0.001;t=2.949,P=0.004)。结论信迪利单抗联合奥沙利铂及卡培他滨联合治疗晚期食管癌患者具有明显的临床效果,能提高患者机体免疫功能,改善患者预后。
Objective To explore the clinical effect of sindilizumab combined with oxaliplatin and capecitabine in the treatment of patients with advanced esophageal cancer.Methods Ninety-eight patients with advanced esophageal cancer who were treated in the Second Affiliated Hospital of Nanyang Medical College from May,2018 to May,2021,they were selected as the subjects of this study and divided into Group A(38 cases)and group B(60 cases)according to the treatment plan.Group A was treated with paclitaxel and cisplatin,while group B was treated with cindilizumab,oxaliplatin and capecitabine.The short-term and long-term curative effects,serum immune function indexes of the two groups were compared before and after treatment.Results The complete remission rate,objective response rate and disease control rate in group B were higher than those in group A(χ^(2)=4.540,P=0.033;χ^(2)=8.425,P=0.004;χ^(2)=4.952,P=0.026).The median progression-free survival and median overall survival of patients in group A were 4.9 and 5.0 months respectively.In group B,median progression-free survival was 8.0 months and median overall survival was 11.5 months.As of the end of follow-up,the median progression-free survival and median overall survival in group B were significantly higher than those in group A(P=0.008、0.017).After treatment,the levels of IgA,IgG and IgM in the two groups were significantly higher than those before treatment(Group A:t=0.332,P=0.741;t=0.141,P=0.888;t=0.557,P=0.579;Group B:t=4.307,P<0.001;t=9.751,P<0.001;t=3.983,P<0.001).After treatment,the levels of IgA,IgG and IgM in Group B were significantly higher than those in Group A(t=2.642,P=0.010;t=7.855,P<0.001;t=2.949,P=0.004).Conclusion The combination of sindilizumab,oxaliplatin and capecitabine in the treatment of patients with advanced esophageal cancer has obvious clinical effect,which can improve the immune function of patients and their prognosis.
作者
石贤菊
石梦楠
丁举乐
SHI Xianju;SHI Mengnan;DING Jule(Department of Medicine,the Second Affiliated Hospital of Nanyang Medical College,Nanyang 473000,China;Department of Ultrasound,Nanyang Second People’s Hospital,Nanyang 473000,China)
出处
《肿瘤基础与临床》
2024年第2期147-150,共4页
journal of basic and clinical oncology
关键词
信迪利单抗
奥沙利铂
卡培他滨
晚期食管癌
sindilizumab
oxaliplatin
capecitabine
advanced esophageal cancer
